Discovery of a New Bioactive Molecule for Neuroblastoma
Article first published online: 1 JUL 2013
© 2013 John Wiley & Sons A/S
Chemical Biology & Drug Design
Volume 82, Issue 2, pages 233–241, August 2013
How to Cite
Leitão, A., Schramm, A. and Eggert, A. (2013), Discovery of a New Bioactive Molecule for Neuroblastoma. Chemical Biology & Drug Design, 82: 233–241. doi: 10.1111/cbdd.12148
- Issue published online: 23 JUL 2013
- Article first published online: 1 JUL 2013
- Accepted manuscript online: 20 APR 2013 12:45AM EST
- Manuscript Accepted: 2 APR 2013
- Manuscript Revised: 14 JAN 2013
- Manuscript Received: 8 APR 2012
- Alexander von Humboldt Stiftung/Foundation
Figure S1. Chemical structures of known Trk binders (a) and the 3D alignment of all molecules using the ATP binding site of as a surrogate model (b).
Figure S2. Extracellular domains of the Trk receptors.
Figure S3. Screening results for five different cell lines showing the dynamic response to the indicated compounds following incubation for 24 h and subsequent analyses of cell viability.
Figure S4. MTT study of cell viability using different concentrations of DMSO (µm).
Figure S5. MTT study of cell viability using different concentrations of DMSO (µm).
Figure S6. Dose-response curves for all cell lines analysed by MTT assay.
Figure S7. Docking constraint shown as a sphere positioned at the amino acid M1160 guiding the hydrogen bonding observed for the crystallographic K252a ligand.
Table S1. Parameters used in FILTER to reduce the number of compounds.
Please note: Wiley-Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.